Nomogram-Based Prediction of Survival in Stage IV Nasopharyngeal Carcinoma: A Retrospective Single-Center Study

<b>Background/Objectives</b>: To assess the pretreatment and posttreatment clinical factors associated with the rate of survival at 1, 3, and 5 years in stage IV nasopharyngeal carcinoma (NPC) patients. <b>Methods</b>: Clinicopathological characteristics of 61 Stage IV NPC patients diagnosed between 2008 and 2022 in a single tertiary medical center were retrospectively reviewed. Univariate and multivariate analyses were performed to evaluate the prognostic factors associated with overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS). A nomogram was developed to forecast DSS. <b>Results</b>: The OS at 1-year, 3-year, and 5-year were 93%, 70%, and 57%, while the DSS at 1-year, 3-year, and 5-year were 93%, 73%, and 58%, whereas the DFS at 1-year, 3-year, and 5-year were 51%, 44%, and 41%, respectively. In multivariate analyses, posttreatment body mass index (BMI) < 21.6 kg/m² (hazard ratio [HR] 2.717, 95% confidence interval [CI] 1.248-5.917, <i>p</i> = 0.012) was an independent indicator for worsened OS. Posttreatment BMI < 21.6 kg/m² (HR 3.003, 95% CI 1.340-6.757, <i>p</i> = 0.008) and pretreatment systemic inflammation response index (SIRI) ≥ 125 (HR 2.841, 95% CI 1.256-6.429, <i>p</i> = 0.012) were independent indicators for worsened DSS. Posttreatment BMI < 21.6 kg/m² (HR 3.650, 95% CI 1.757-7.576, <i>p</i> = 0.001), change in BMI < -1.93 kg/m² (HR 3.731, 95% CI 1.642-8.475, <i>p</i> = 0.002), and pretreatment SIRI ≥ 125 (HR 3.541, 95% CI 1.717-7.304, <i>p</i> = 0.001) were independent indicators for worsened DFS. A nomogram was created to predict DSS using posttreatment BMI and pretreatment SIRI. <b>Conclusions</b>: Associations with survival were observed between posttreatment BMI and OS, DSS, and DFS; pretreatment SIRI and DSS/DFS; and changes in BMI and DFS among patients with stage IV NPC. The developed nomogram aids in survival prediction.